Autologous stem-cell transplantation in patients with HIV-related lymphoma

Pascual Balsalobre, José L. Díez-Martín, Alessandro Re, Mariagrazia Michieli, José M. Ribera, Carmen Canals, Anne Rosselet, Eulogio Conde, Rosario Varela, Kate Cwynarski, Ian Gabriel, Philippe Genet, Gaelle Guillerm, Bernardino Allione, Augustin Ferrant, Pierre Biron, Ildefonso Espigado, David Serrano, Anna Sureda

Research output: Contribution to journalArticlepeer-review


Purpose: Peripheral-blood autologous stem-cell transplantation (ASCT) in patients with HIV-related lymphoma (HIV-Ly) has been reported as a safe and useful procedure. Herein we report the European Group for Blood and Marrow Transplantation experience on patients with HIV-Ly undergoing ASCT. Patients and Methods: This was a retrospective, multicentric, registry-based analysis. Results: Since 1999, 68 patients from 20 institutions (median age, 41 years; range, 29 to 62 years) were included, diagnosed with non-Hodgkin's lymphoma (NHL; n = 50) or Hodgkin's lymphoma (n = 18). At the time of ASCT, 16 patients were in first complete remission (CR1); 44 patients were in CR more than 1, partial remission, or chemotherapy-sensitive relapse (chemo-S); and eight patients had chemotherapy-resistant disease. The median number of CD34 + cells infused was 4.5 × 106/kg (range, 1.6 to 21.2 × 106/kg). Median time to neutrophil and platelet engraftment were 11 days (range, 8 to 36 days) and 14 days (range, 6 to 455 days), respectively, with a cumulative incidence (CI) at 1 year of 95.6% and 87%, respectively. CI of nonrelapse mortality (NRM) was 7.5% at 12 months after ASCT, mainly because of bacterial infections. CI of relapse was 30.4% at 24 months, statistically related with not being in CR at ASCT (relative risk [RR] = 3.6), NHL histology other than diffuse large B-cell lymphoma (RR = 3.4), and use of more than two previous treatment lines (RR = 3). At a median follow-up of 32 months (range, 2 to 81 months), progression-free survival (PFS) was 56%. Patients not in CR or with refractory disease at ASCT had poorer PFS (RR = 2.4 and 4.8, respectively). Conclusion: Similarly to HIV-negative patients with lymphoma, ASCT is a useful treatment for patients with HIV-Ly and is associated with low NRM, mainly when performed in early stages and chemo-S disease.

Original languageEnglish
Pages (from-to)2192-2198
Number of pages7
JournalJournal of Clinical Oncology
Issue number13
Publication statusPublished - May 1 2009

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)


Dive into the research topics of 'Autologous stem-cell transplantation in patients with HIV-related lymphoma'. Together they form a unique fingerprint.

Cite this